Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology
High‐throughput genomic analyses are being implemented in clinical practice. MODIFY is a retrospective study of the first introduction of genomic profiling and molecular tumor boards in the country of Luxembourg. The primary objective was to assess whether patients derived a clinical benefit by meas...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13785 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155097545244672 |
|---|---|
| author | Michaël Dang Anna Schritz Nikolai Goncharenko Guy Berchem |
| author_facet | Michaël Dang Anna Schritz Nikolai Goncharenko Guy Berchem |
| author_sort | Michaël Dang |
| collection | DOAJ |
| description | High‐throughput genomic analyses are being implemented in clinical practice. MODIFY is a retrospective study of the first introduction of genomic profiling and molecular tumor boards in the country of Luxembourg. The primary objective was to assess whether patients derived a clinical benefit by measuring the percentage of patients who presented a progression‐free survival (PFS) on matched therapy (PFS2) 1.3‐fold longer than PFS on previous therapy (PFS1). A total of 94 patients were included. In total, 45 patients (53.57% of patients with successful next‐generation sequencing [NGS] analysis) were found to have an actionable mutation. Of these, 11 patients received the treatment recommended by the molecular tumor board, another 12 received best‐supportive care, and 20 were treated with conventional therapy. PFS2 and PFS1 data were available for eight patients. The PFS2/PFS1 ratio was ≥ −1.3 in 62.5% (n = 5/8; CI [30.38, 86.51]) of patients; three patients showed a partial response, and median overall survival (OS) was 7.3 months. Although the examined population was small, this study further supports evidence indicating that patients with advanced cancer benefit from molecular profiling and targeted therapy. |
| format | Article |
| id | doaj-art-2e3a161633fe42fdaedc406c866d0f81 |
| institution | OA Journals |
| issn | 1574-7891 1878-0261 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj-art-2e3a161633fe42fdaedc406c866d0f812025-08-20T02:25:02ZengWileyMolecular Oncology1574-78911878-02612025-05-011951508151610.1002/1878-0261.13785Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncologyMichaël Dang0Anna Schritz1Nikolai Goncharenko2Guy Berchem3Department of Oncology Centre Hospitalier de Luxembourg (CHL) LuxembourgLuxembourg Institute of Health (LIH) LuxembourgInstitut National du Cancer (INC) Luxembourg LuxembourgDepartment of Oncology Centre Hospitalier de Luxembourg (CHL) LuxembourgHigh‐throughput genomic analyses are being implemented in clinical practice. MODIFY is a retrospective study of the first introduction of genomic profiling and molecular tumor boards in the country of Luxembourg. The primary objective was to assess whether patients derived a clinical benefit by measuring the percentage of patients who presented a progression‐free survival (PFS) on matched therapy (PFS2) 1.3‐fold longer than PFS on previous therapy (PFS1). A total of 94 patients were included. In total, 45 patients (53.57% of patients with successful next‐generation sequencing [NGS] analysis) were found to have an actionable mutation. Of these, 11 patients received the treatment recommended by the molecular tumor board, another 12 received best‐supportive care, and 20 were treated with conventional therapy. PFS2 and PFS1 data were available for eight patients. The PFS2/PFS1 ratio was ≥ −1.3 in 62.5% (n = 5/8; CI [30.38, 86.51]) of patients; three patients showed a partial response, and median overall survival (OS) was 7.3 months. Although the examined population was small, this study further supports evidence indicating that patients with advanced cancer benefit from molecular profiling and targeted therapy.https://doi.org/10.1002/1878-0261.13785genomic profilingmatched therapyPFS ratioprecision oncology |
| spellingShingle | Michaël Dang Anna Schritz Nikolai Goncharenko Guy Berchem Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology Molecular Oncology genomic profiling matched therapy PFS ratio precision oncology |
| title | Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology |
| title_full | Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology |
| title_fullStr | Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology |
| title_full_unstemmed | Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology |
| title_short | Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology |
| title_sort | impact of molecular diagnostics and targeted cancer therapy on patient outcomes modify a retrospective study of the implementation of precision oncology |
| topic | genomic profiling matched therapy PFS ratio precision oncology |
| url | https://doi.org/10.1002/1878-0261.13785 |
| work_keys_str_mv | AT michaeldang impactofmoleculardiagnosticsandtargetedcancertherapyonpatientoutcomesmodifyaretrospectivestudyoftheimplementationofprecisiononcology AT annaschritz impactofmoleculardiagnosticsandtargetedcancertherapyonpatientoutcomesmodifyaretrospectivestudyoftheimplementationofprecisiononcology AT nikolaigoncharenko impactofmoleculardiagnosticsandtargetedcancertherapyonpatientoutcomesmodifyaretrospectivestudyoftheimplementationofprecisiononcology AT guyberchem impactofmoleculardiagnosticsandtargetedcancertherapyonpatientoutcomesmodifyaretrospectivestudyoftheimplementationofprecisiononcology |